<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21603651</article-id><article-id pub-id-type="pmc">3095594</article-id><article-id pub-id-type="publisher-id">PONE-D-11-02192</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0019252</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biotechnology</subject><subj-group><subject>Bioengineering</subject><subj-group><subject>Medical Devices</subject></subj-group></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group><subj-group><subject>Immunity</subject><subj-group><subject>Vaccination</subject><subj-group><subject>Vaccines</subject><subject>Vaccine Development</subject></subj-group></subj-group></subj-group><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunoassays</subject></subj-group></subj-group><subj-group><subject>Immune Response</subject></subj-group></subj-group><subj-group><subject>Clinical research design</subject><subj-group><subject>Clinical trials</subject><subj-group><subject>Phase I</subject></subj-group></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Medical Devices</subject></subj-group></subj-group><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV prevention</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Public Health</subject><subj-group><subject>Preventive Medicine</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>
<italic>In Vivo</italic> Electroporation Enhances the Immunogenicity
of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers</article-title><alt-title alt-title-type="running-head">EP Enhances DNA Immunogenicity in
Humans</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vasan</surname><given-names>Sandhya</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hurley</surname><given-names>Arlene</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Schlesinger</surname><given-names>Sarah J.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hannaman</surname><given-names>Drew</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gardiner</surname><given-names>David F.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dugin</surname><given-names>Daniel P.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boente-Carrera</surname><given-names>Mar</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vittorino</surname><given-names>Roselle</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caskey</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Andersen</surname><given-names>Johanne</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Yaoxing</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>Josephine H.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tarragona-Fiol</surname><given-names>Tony</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gill</surname><given-names>Dilbinder K.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cheeseman</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Lorna</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dally</surname><given-names>Len</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Harriet H.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kopycinski</surname><given-names>Jakub T.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gilmour</surname><given-names>Jill</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fast</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bernard</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>David D.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Aaron Diamond AIDS Research Center, New York,
New York, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>The Rockefeller University, New York, New
York, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Ichor Medical Systems, Inc., San Diego,
California, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>International AIDS Vaccine Initiative, New
York, New York, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>International AIDS Vaccine Initiative, Human
Immunology Laboratory, Imperial College, London, United Kingdom</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>The EMMES Corporation, Rockville, Maryland,
United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Lu</surname><given-names>Shan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Massachusetts Medical Center, United States of
America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>svasan@adarc.org</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: SV DG DH AH SS YH PF RB DDH.
Performed the experiments: SV AH DPD SS MC JA MBC RV TT DKG HC LC. Analyzed
the data: SV AH DPD C. Schmidt HHP LD C. Smith JTK MBC JG. Contributed
reagents/materials/analysis tools: YH RB DH. Wrote the paper: DDH YH JC LD
C. Smith. Wrote the first draft of the manuscript and prepared figures: SV.
</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2011</year></pub-date><volume>6</volume><issue>5</issue><elocation-id>e19252</elocation-id><history><date date-type="received"><day>31</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2011</year></date></history><permissions><copyright-statement>Vasan et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>DNA-based vaccines have been safe but weakly immunogenic in humans to
date.</p></sec><sec><title>Methods and Findings</title><p>We sought to determine the safety, tolerability, and immunogenicity of ADVAX,
a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by
<italic>in vivo</italic> electroporation (EP) in a Phase-1,
double-blind, randomized placebo-controlled trial in healthy volunteers.
Eight volunteers each received 0.2 mg, 1 mg, or 4 mg ADVAX or saline placebo
via EP, or 4 mg ADVAX via standard intramuscular injection at weeks 0 and 8.
A third vaccination was administered to eleven volunteers at week 36. EP was
safe, well-tolerated and considered acceptable for a prophylactic vaccine.
EP delivery of ADVAX increased the magnitude of HIV-1-specific cell mediated
immunity by up to 70-fold over IM injection, as measured by gamma interferon
ELISpot. The number of antigens to which the response was detected improved
with EP and increasing dosage. Intracellular cytokine staining analysis of
ELISpot responders revealed both CD4&#x0002b; and CD8&#x0002b; T cell responses,
with co-secretion of multiple cytokines.</p></sec><sec><title>Conclusions</title><p>This is the first demonstration in healthy volunteers that EP is safe,
tolerable, and effective in improving the magnitude, breadth and durability
of cellular immune responses to a DNA vaccine candidate.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/show/NCT00545987">NCT00545987</ext-link>
</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In 1993, Ulmer <italic>et al.</italic> first described the ability of naked plasmid
DNA encoding an influenza protein to induce a protective immune response in mice
<xref rid="pone.0019252-Ulmer1" ref-type="bibr">[1]</xref>, likely
through transfection of myocytes and cross-presentation to antigen-presenting cells
(APCs), as well as direct uptake of apoptotic cells by APCs <xref rid="pone.0019252-Donnelly1" ref-type="bibr">[2]</xref>. Since then, DNA vaccines have
been utilized in a variety of experimental clinical settings including candidate
vaccines against cancer, malaria, hepatitis B, and HIV-1 <xref rid="pone.0019252-Rice1" ref-type="bibr">[3]</xref>&#x02013;<xref rid="pone.0019252-Graham1" ref-type="bibr">[7]</xref>. Unfortunately, the robust
cellular and humoral immunogenicity elicited by standard intramuscular injection of
DNA vaccines in small animals has not translated to humans, as stand alone DNA
vaccines have been weakly immunogenic in clinical trials. Although a few DNA
vaccines have been licensed for use in animals, there are currently no DNA vaccines
licensed for human use <xref rid="pone.0019252-Kutzler1" ref-type="bibr">[8]</xref>. Consequently, the focus of many DNA vaccine strategies
has shifted to their ability to &#x0201c;prime&#x0201d; the immune response before
boosting with a recombinant live viral vector, such as adenovirus or modified
vaccinia Ankara (MVA) <xref rid="pone.0019252-McConkey1" ref-type="bibr">[9]</xref>&#x02013;<xref rid="pone.0019252-Goonetilleke1" ref-type="bibr">[12]</xref>, or with protein <xref rid="pone.0019252-Wang2" ref-type="bibr">[13]</xref>.</p><p>DNA vaccines offer several advantages over vaccines based on recombinant live viral
vectors. Subjects may have pre-existing immunity to the viral vector itself, as in
the case with adenovirus serotype 5-based vaccines, thereby limiting their
effectiveness <xref rid="pone.0019252-Nwanegbo1" ref-type="bibr">[14]</xref>, <xref rid="pone.0019252-Mast1" ref-type="bibr">[15]</xref>. Anti-vector immunity also develops rapidly after
vaccination with recombinant viral vectors, effectively limiting the number
administrations <xref rid="pone.0019252-Santra1" ref-type="bibr">[16]</xref>. DNA vaccines are not limited by such constraints, and
can be safely administered repeatedly to humans <xref rid="pone.0019252-Schalk1" ref-type="bibr">[17]</xref>. In addition, DNA vaccines can
be rapidly produced using relatively simple, low-cost manufacturing procedures and
exhibit a favorable thermostability profile. Such features would confer obvious
advantages in large-scale global vaccination campaigns.</p><p>One major factor thought to contribute to the weak immunogenicity of DNA vaccines in
humans is the relatively poor uptake of the vaccine by myocytes and other cells when
injected intramuscularly (IM) <xref rid="pone.0019252-Manam1" ref-type="bibr">[18]</xref>. <italic>In vivo</italic> electroporation (EP) is a
technique that significantly increases the immunogenicity of DNA vaccines via
co-administration of small, localized electrical fields to increase the transfection
efficiency of the injected DNA <xref rid="pone.0019252-Mathiesen1" ref-type="bibr">[19]</xref>, <xref rid="pone.0019252-Widera1" ref-type="bibr">[20]</xref> and the recruitment of immune cells such as dendritic
cells, T and B lymphocytes to the site of immunization <xref rid="pone.0019252-Babiuk1" ref-type="bibr">[21]</xref>, <xref rid="pone.0019252-Liu1" ref-type="bibr">[22]</xref>. Animal studies in animals have
shown that <italic>in vivo</italic> EP increases the immunogenicity of DNA vaccines
encoding a number of antigens <xref rid="pone.0019252-Babiuk2" ref-type="bibr">[23]</xref>&#x02013;<xref rid="pone.0019252-Chen1" ref-type="bibr">[32]</xref>. In humans, <italic>in vivo</italic> EP has been
successful at delivering chemotherapeutic agents directly to tumors <xref rid="pone.0019252-Sersa1" ref-type="bibr">[33]</xref>. More recently,
DNA vaccines encoding tumor antigens have been administered to cancer patients by EP
as potential immunotherapy <xref rid="pone.0019252-Stevenson1" ref-type="bibr">[34]</xref>, <xref rid="pone.0019252-Low1" ref-type="bibr">[35]</xref>.</p><p>ADVAX is a clade C/B' DNA vaccine candidate against HIV-1 <xref rid="pone.0019252-Huang1" ref-type="bibr">[36]</xref>. When previously administered IM
as a three vaccination regimen without EP to healthy volunteers at three different
dosage levels, it proved to be safe but weakly immunogenic, inducing low-level,
transient cellular responses, but no humoral response <xref rid="pone.0019252-Vasan1" ref-type="bibr">[37]</xref>. In this study, we sought to
determine whether intramuscular administration of ADVAX via <italic>in vivo</italic>
EP would be safe, tolerable and acceptable in healthy volunteers, and whether EP
delivery would enhance immunogenicity compared to standard IM injection.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study Setting</title><p>The study was conducted at the Rockefeller University Hospital in New York City,
USA.</p></sec><sec id="s2b"><title>Participants</title><p>Healthy men and women aged 18&#x02013;60 years were eligible for participation if
they were not at high risk for HIV-1, as defined by having none of the following
activities in the six months prior to enrollment: unprotected vaginal or anal
sex with a known HIV-1-infected person or casual partner, injection drug use,
acquisition of a sexually transmitted disease, or sex work for money or drugs.
Participants agreed to safe sexual practices and to effective contraception to
avoid pregnancy throughout the duration of the 14-month study. Participants had
to demonstrate a clear understanding of the possibility of HIV-1 seropositivity
due to vaccine-induced antibodies. Exclusion criteria included chronic medical
conditions, clinically significant abnormal laboratory parameters, infection
with Hepatitis B or C virus, recent receipt of a vaccine or blood transfusion,
any implanted electronic stimulation device, or deltoid skin fold thickness of
greater than 40 mm.</p></sec><sec id="s2c"><title>Ethics Statement</title><p>The study was approved by the Institutional Review Board of the Rockefeller
University Hospital. All participants in this study provided written informed
consent after appropriate review, discussion and counseling by the clinical
study team. The trial was conducted in partnership with Ichor Medical Systems,
Inc. and the International AIDS Vaccine Initiative (IAVI), and sponsored by the
Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery. The
study was conducted in compliance with International Conference on Harmonisation
- Good Clinical Practice (ICH-GCP) guidelines.</p></sec><sec id="s2d"><title>Interventions</title><sec id="s2d1"><title>Candidate Vaccine</title><p>The ADVAX vaccine candidate is a 1&#x02236;1 mixture of two DNA plasmids
containing clade C/B', codon-optimized HIV-1 gene sequences. The first
plasmid expresses Env under the CMV promoter and Gag under the human
elongation factor 1&#x003b1; (PhEF1&#x003b1;) promoter, while the second expresses
Pol under the CMV promoter and a Nef-Tat fusion under the PhEF1&#x003b1;
promoter, as previously described <xref rid="pone.0019252-Huang1" ref-type="bibr">[36]</xref>. A Phase-1 clinical
trial of ADVAX injected IM has been reported previously <xref rid="pone.0019252-Vasan1" ref-type="bibr">[37]</xref>.</p></sec><sec id="s2d2"><title>Electroporation Procedure</title><p>The disposable electroporation cartridge was loaded with placebo or ADVAX by
the Rockefeller University Hospital Pharmacy and then adjusted to one of
three depth settings, corresponding to pre-defined ranges in skin fold
thickness. The cartridge was loaded into the EP device and applied to the
deltoid muscle. Intramuscular administration of ADVAX or placebo was
followed immediately by the application of electrical stimulation
(TriGrid<sup>TM</sup> Delivery System, Ichor Medical Systems, San Diego,
CA). The spacing of the TriGrid<sup>TM</sup> electrode array was 6 mm in a
diamond-shaped configuration, and the electrical field was applied at an
amplitude of 250 V/cm of electrode spacing for a 40 msec total duration
applied as three pulses over a 400 msec interval, resulting in brief deltoid
muscle contractions. All electroporation procedures were performed by a
single, trained physician.</p></sec><sec id="s2d3"><title>Study Design</title><p>The study design is summarized in <xref ref-type="table" rid="pone-0019252-t001">Table 1</xref>. This study was randomized,
dose-escalating, and double blind with respect to active vaccine candidate
or saline placebo, but not with respect to dose group or mode of
administration (IM versus EP). The randomization schedule was prepared by
the Rockefeller University Hospital Pharmacy, using a web-based program at
randomization.com. Each of the 3 cohorts consisted of 2 or 3 subjects
randomized to receive 4 mg ADVAX IM (HD-IM), 2 or 3 subjects randomized to
receive placebo EP, and 8 subjects receiving ADVAX EP. The dose of ADVAX
delivered by EP varied with each cohort in a dose-escalating design: 0.2 mg
(LD-EP), 1 mg (MD-EP) or 4 mg (HD-EP). Dosage levels were based on
previously tested concentrations of ADVAX <xref rid="pone.0019252-Vasan1" ref-type="bibr">[37]</xref>, with the intent to
determine whether EP delivery of ADVAX provided any dose-sparing effect as
measured by immunogenicity. In total, 40 subjects were enrolled. Blinded
safety and tolerability in each cohort were evaluated by an independent Data
and Safety Monitoring Board in a blinded manner prior to initiation of
enrollment of the next dosage cohort. After all volunteers had received both
scheduled vaccinations, the trial was amended to include a third vaccination
at week 36 in volunteers randomized to receive EP in the high-dose group
cohort (n&#x0200a;=&#x0200a;8 ADVAX, n&#x0200a;=&#x0200a;3
placebo), in order to determine whether a third vaccination at the highest
dose could further enhance immunogenicity. The protocol for this trial and
supporting CONSORT checklist are available as supporting information; see
<xref ref-type="supplementary-material" rid="pone.0019252.s004">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0019252.s003">Protocol S1</xref>.</p><table-wrap id="pone-0019252-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.t001</object-id><label>Table 1</label><caption><title>Study Design.</title></caption><alternatives><graphic id="pone-0019252-t001-1" xlink:href="pone.0019252.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Placebo (Saline/EP)</td><td align="left" rowspan="1" colspan="1">ADVAX IM (4.0 mg)</td><td align="left" rowspan="1" colspan="1">ADVAX EP</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Group 1</bold>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">8 (0.2 mg)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Group 2</bold>
</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">8 (1.0 mg)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Group 3</bold>
</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">8 (4.0 mg)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Study Total</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>24</bold>
</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="s2e"><title>Objectives</title><p>The primary objective was to evaluate the safety and tolerability of ADVAX
delivered intramuscularly via <italic>in vivo</italic> EP at one of three dose
levels versus ADVAX delivered by standard intramuscular injection and placebo
delivered via EP in healthy HIV-uninfected adults. The secondary objective was
to evaluate the humoral and cellular immunogenicity of ADVAX-EP versus
ADVAX-IM.</p></sec><sec id="s2f"><title>Outcomes</title><sec id="s2f1"><title>Vaccine Reactogenicity, Safety, Tolerability, and Acceptability</title><p>Primary endpoints were designed to evaluate the safety of ADVAX in human
volunteers. Local reactogenicity (including pain, tenderness, erythema,
edema, skin damage, induration, and formation of crust, scab or scar) and
systemic reactogenicity (including fever, chills, headache, nausea,
vomiting, malaise, myalgia, arthralgia, and rash) were assessed within
30&#x02013;45 minutes after each vaccination in the clinic, by telephone three
days following vaccination, and by history and physical examination one week
after vaccination. Subjects were monitored for adverse events, general
health and clinical laboratory parameters at each study visit. Subjects
randomized to receive ADVAX or placebo via EP were asked to complete a
questionnaire rating their pain on a five-point scale at three time points
during and after the EP procedure, as well as the perceived acceptability of
the procedure for use in the setting of preventive immunization 30&#x02013;45
minutes after each vaccination.</p></sec><sec id="s2f2"><title>Immunological Analyses</title><p>Secondary endpoints evaluated the cellular and humoral immunogenicity of
ADVAX at 0, 1, 2, and 4 weeks after each vaccination as well as at weeks 16,
24, 36, 48, and 56. Cellular immunogenicity was assessed by IFN&#x003b3; ELISpot
on frozen peripheral blood mononuclear cells (PBMCs) stimulated by peptides
matched to the Clade C/B' sequences encoded in the vaccine as
previously described <xref rid="pone.0019252-Vasan1" ref-type="bibr">[37]</xref>.</p><p>For each pool, the ELISpot value was defined as the mean replicate (maximum
4) count minus the mean background count. Four criteria had to be fulfilled
for an ELISpot value to be considered positive: 1) for each peptide pool, a
single value had to be greater than the maximum of all pre-vaccination and
all placebo values for that pool, and &#x0003e;38 Spot Forming Units
(SFU)/10<sup>6</sup> cells; 2) the mean count had to be &#x0003e;4 times the
mean background SFU; 3) the mean background had to be &#x0003c;55
SFU/10<sup>6</sup> cells; and 4) the coefficient of variation had to be
&#x02264;70&#x00025; across the replicate wells.</p><p>ELISpot-positive samples at the peak responding time point in the high-dose
EP group, along with the respective baseline samples, were tested for
phenotype, cytokine secretion, and antigen-specific proliferation using
polychromatic flow cytometry. Cryopreserved PBMCs were co-incubated with 2
&#x000b5;g peptide pools or 1 &#x000b5;g SEB (Sigma-Aldrich, St. Louis, MO),
CD107 PECy5 (Becton Dickinson, San Jose, CA), Brefeldin A (Sigma-Aldrich,
Poole Dorset, UK) and BD Golgistop (Becton Dickinson, San Jose, CA) for 6
hours at 37&#x000b0;C. Cells were stained with 50 &#x000b5;L LIVE/DEAD&#x000ae;
Fixable Blue Dead Cell Stain Kit (Invitrogen, Eugene, OR), anti-CD4 QD605,
anti-CD8 pacific orange (Invitrogen, Paisley, UK), anti-CD27 FITC (Becton
Dickinson, San Jose, CA), and anti-CD45RO (Beckman Coulter, High Wycombe,
UK), and stained intracellularly with anti-CD3 QD655 (Invitrogen, Paisley,
UK), anti-IFN-&#x003b3; PE Cy7, anti-MIP-1&#x003b2; PE, anti-TNF-&#x003b1; A700 and
anti-IL-2 APC (Becton Dickinson, San Jose, CA). At least 500,000 events were
acquired on a custom-built BD LSR II cytometer. Data were analyzed using
FlowJo (Treestar), PESTLE and SPICE (courtesy of Mario Roederer, Vaccine
Research Center) software. A response was considered positive if it
fulfilled the following three criteria: 1) the percentage of
cytokine-producing cells after antigen stimulation was at least three times
greater than the percentage of cytokine-producing cells in the mock pool at
the same post-vaccination time point, 2) the response to the same antigen
was negative at pre-vaccination baseline, and 3) the absolute response was
&#x02265;0.05&#x00025;.</p></sec><sec id="s2f3"><title>Humoral immunogenicity</title><p>Binding antibodies to clade C gp120 (NIH AIDS Reagent Program) were assessed
by ELISA at pre-vaccination baseline and two weeks after each vaccination,
as previously described <xref rid="pone.0019252-Vasan1" ref-type="bibr">[37]</xref>. In parallel, anti-gp160, anti-p24, or anti-gp36
Group M/O antibodies were assessed using the Genetic Systems<sup>TM</sup>
HIV-1| HIV-2 PLUS O EIA Kit (Bio-Rad Laboratories, Hercules, CA), at the New
York State Department of Health. Samples that were positive were further
evaluated by the Genetic Systems<sup>TM</sup> HIV-1 Western Blot Kit
(Bio-Rad Laboratories, Hercules, CA) and for viral load quantification using
the Roche Amplicor HIV-1 Monitor v1.5 RNA-PCR Kit (Roche Diagnostic Systems,
Indianapolis, IN) to differentiate a response to vaccine from incident HIV-1
infection. Results were monitored by an independent physician to maintain
blinding of the clinical study team.</p></sec></sec><sec id="s2g"><title>Statistical Methods</title><p>Data from all participants, including those lost to follow up and those not
completing the vaccination series, were included in the analyses, as per the
participant flow diagram in <xref ref-type="fig" rid="pone-0019252-g001">Figure
1</xref>. Fisher's exact test was used to test differences in the rate
of local and systemic reactogenicity events between groups, and the
Cochran-Armitage test was used to investigate trends in event rates with
increasing ADVAX EP dosage. Differences in magnitude of ELISpot responses
between each EP dose group and the IM group were analyzed using the
non-parametric Wilcoxon 2-sample test (t approximation), with significance set
at p&#x0003c;0.017 to allow for three tests per antigen. All tests are 2-tailed.</p><fig id="pone-0019252-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.g001</object-id><label>Figure 1</label><caption><title>Participant Flow Diagram.</title></caption><graphic xlink:href="pone.0019252.g001"/></fig></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Recruitment and Participant Flow</title><p>Enrollment occurred from October 2007 through October 2008. As shown in <xref ref-type="fig" rid="pone-0019252-g001">Figure 1</xref>, 73 volunteers were
screened for this study, of which 40 were enrolled. The majority of the 33
screen failures were due to abnormalities on screening laboratories or
urinalysis. All volunteers completed their vaccination schedule, but three
participants did not complete the trial for reasons unrelated to the vaccine or
the study (lost to follow-up). Baseline demographic and clinical characteristics
for all trial participants are summarized in <xref ref-type="table" rid="pone-0019252-t002">Table 2</xref>.</p><table-wrap id="pone-0019252-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.t002</object-id><label>Table 2</label><caption><title>Volunteer Demographics.</title></caption><alternatives><graphic id="pone-0019252-t002-2" xlink:href="pone.0019252.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Method of Administration</td><td colspan="4" align="left" rowspan="1">Electroporation</td><td align="left" rowspan="1" colspan="1">IM</td><td align="left" rowspan="1" colspan="1">Total</td></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">
<bold>ADVAX Dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.2</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.0</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.0</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Placebo</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.0</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Number of Volunteers</bold>
</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">40</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Timing of Administration
(week)</bold>
</td><td align="left" rowspan="1" colspan="1">0, 8</td><td align="left" rowspan="1" colspan="1">0, 8</td><td align="left" rowspan="1" colspan="1">0, 8, 36<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">0, 8, 36<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">0, 8</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ethnicity</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Not Hispanic and Not Latino</bold>
</td><td align="left" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Black or African American</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Multiracial</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hispanic or Latino</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Multiracial</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other/Unknown</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age at enrollment (years)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Mean</bold>
</td><td align="left" rowspan="1" colspan="1">33.0</td><td align="left" rowspan="1" colspan="1">29.9</td><td align="left" rowspan="1" colspan="1">37.1</td><td align="left" rowspan="1" colspan="1">33.6</td><td align="left" rowspan="1" colspan="1">39.1</td><td align="left" rowspan="1" colspan="1">34.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Range</bold>
</td><td align="left" rowspan="1" colspan="1">18&#x02013;59</td><td align="left" rowspan="1" colspan="1">21&#x02013;53</td><td align="left" rowspan="1" colspan="1">24&#x02013;52</td><td align="left" rowspan="1" colspan="1">19&#x02013;52</td><td align="left" rowspan="1" colspan="1">21&#x02013;58</td><td align="left" rowspan="1" colspan="1">18&#x02013;59</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Body Weight (kg)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Mean</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>76.8</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>68.4</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>78.4</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>82.6</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>77.0</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>76.6</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Range</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>58&#x02013;100</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>52&#x02013;85</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>46&#x02013;115</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>53&#x02013;120</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>50&#x02013;99</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>46&#x02013;120</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>&#x0002a;Only those volunteers in the high dose cohort (HD-EP,
n&#x0200a;=&#x0200a;8, and Placbeo-EP,
n&#x0200a;=&#x0200a;3) received a 3<sup>rd</sup> vaccination at
Week 36.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Reactogenicity and Adverse Events</title><p>Overall, ADVAX delivered by standard IM injection or by EP was safe and
well-tolerated, although most volunteers in all dose groups reported
mild-moderate local pain and/or tenderness. The proportion of volunteers with
mild-moderate local pain and/or tenderness as assessed by the clinical study
team within 30&#x02013;45 minutes of vaccination differed significantly
(p&#x0003c;.001) among the 5 dose groups, being smaller in the HD-IM group (2/8) than
in any of the EP groups (6/8 EP-placebo and 8/8 each ADVAX EP group). There was
no significant difference in self-assessed local reactogenicity within 4 days
following the vaccination (p&#x0200a;=&#x0200a;0.291). Most local reactions
resolved within one day; all resolved within 7 days. The maximum severity of
systemic reactogenicity events after any ADVAX or placebo administration was
mild when assessed within 30&#x02013;45 minutes of vaccination in clinic and
moderate within 4 days following vaccination when assessed by the volunteer. All
systemic reactions resolved within 2 days. Differences in systemic
reactogenicity among the 5 study groups were not statistically significant
(clinic: p&#x0200a;=&#x0200a;0.252, self-assessment:
p&#x0200a;=&#x0200a;0.291).</p><p>Of the 139 non-serious adverse events, 123 (89&#x00025;) were mild. One volunteer,
who was in the MD-EP group, and who received saline placebo, experienced a
serious adverse event (hospitalization for coronary artery disease) 109 days
after his second vaccination, which was unrelated to study vaccine or procedure.
None of the moderate or severe adverse events were related to vaccination, and
none of the volunteers discontinued the study due to adverse events. The
distribution of mild and moderate adverse events was not significantly different
among the 5 dose groups (p&#x0200a;=&#x0200a;0.414, Fisher's exact
2-tailed test). <xref ref-type="supplementary-material" rid="pone.0019252.s002">Table S1</xref> summarizes all adverse events by System Organ Class (SOC).
There were no differences in clinical laboratory parameters among study groups
or trends within any study group over time. None of the volunteers developed
anti-double-stranded DNA antibodies.</p></sec><sec id="s3c"><title>Tolerability and Acceptability of Electroporation</title><p>
<xref ref-type="fig" rid="pone-0019252-g002">Figure 2</xref> summarizes the
tolerability (Panel A) and acceptability (Panel B) of the electroporation
procedure. The intensity of pain was greatest immediately after electrical
stimulation of the muscle, but improved rapidly within 30 minutes post
vaccination. For all 3 assessments, the proportions of volunteers reporting
uncomfortable, intense or severe discomfort were not significantly different
among the 4 EP dose groups. The level of tolerability was independent of age,
gender, body weight, skin fold thickness, vaccination in dominant versus
non-dominant arm, or sequence of vaccination. The majority of participants
indicated that they would undergo the procedure for a vaccination to protect
against either a life threatening illness for which we have no alternative
vaccine such as HIV-1 (97&#x00025;), or, to improve the protection achievable
with existing vaccines against a non-life threatening illness such as influenza
(91&#x00025;).</p><fig id="pone-0019252-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.g002</object-id><label>Figure 2</label><caption><title>Tolerability and Acceptability of Electroporation.</title><p>Volunteers randomized to receive ADVAX or placebo via EP completed a
questionnaire to rate the tolerability of the procedure on a 5 point
pain scale at three different time points during and after EP (Panel A),
and the acceptability of the procedure for future vaccination (Panel B).
Results represent a total of 75 responses from 32 volunteers.</p></caption><graphic xlink:href="pone.0019252.g002"/></fig></sec><sec id="s3d"><title>Cellular Immunogenicity</title><p>IFN&#x003b3; ELISpot results are summarized in <xref ref-type="table" rid="pone-0019252-t003">Table 3</xref>. Positive IFN&#x003b3; ELISpot responses
after two vaccinations occurred in 0/8 (0&#x00025;), 1/8 (13&#x00025;), 5/8
(63&#x00025;), and 6/8 (75&#x00025;) volunteers in the HD-IM, LD-EP, MD-EP and
HD-EP groups, respectively. The response rate in the HD-EP group increased to
7/8 (88&#x00025;) after the third vaccination. There were no positive responses
to any peptide pool among the placebo recipients, by definition. There was a
dose-dependent increase in the number of antigens to which a response was
detected.</p><table-wrap id="pone-0019252-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.t003</object-id><label>Table 3</label><caption><title>Summary of IFN&#x003b3; ELISpot Positive Responses.</title></caption><alternatives><graphic id="pone-0019252-t003-3" xlink:href="pone.0019252.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Group</td><td align="left" rowspan="1" colspan="1">EP Placebo</td><td align="left" rowspan="1" colspan="1">IM High</td><td align="left" rowspan="1" colspan="1">EP Low</td><td align="left" rowspan="1" colspan="1">EP Mid</td><td align="left" rowspan="1" colspan="1">EP High</td></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">
<bold>ADVAX Dose</bold>
</td><td align="left" rowspan="1" colspan="1">0 mg</td><td align="left" rowspan="1" colspan="1">4.0 mg</td><td align="left" rowspan="1" colspan="1">0.2 mg</td><td align="left" rowspan="1" colspan="1">1.0 mg</td><td align="left" rowspan="1" colspan="1">4.0 mg</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Volunteers with Positive
Responses</bold>
</td><td align="left" rowspan="1" colspan="1">0/8 (0&#x00025;)</td><td align="left" rowspan="1" colspan="1">0/8 (0&#x00025;)</td><td align="left" rowspan="1" colspan="1">1/8 (13&#x00025;)</td><td align="left" rowspan="1" colspan="1">5/8 (63&#x00025;)</td><td align="left" rowspan="1" colspan="1">7/8 (88&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Env</bold> (SFU/million)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mean</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">224</td><td align="left" rowspan="1" colspan="1">273</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">median</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">201</td><td align="left" rowspan="1" colspan="1">275</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25&#x02013;75&#x00025;ile</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">176&#x02013;229</td><td align="left" rowspan="1" colspan="1">186&#x02013;336</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">range</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">161&#x02013;440</td><td align="left" rowspan="1" colspan="1">150&#x02013;595</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pol</bold>(SFU/million)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mean</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">84</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">median</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">78</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25&#x02013;75&#x00025;ile</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">46&#x02013;66</td><td align="left" rowspan="1" colspan="1">59&#x02013;115</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">range</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">39&#x02013;74</td><td align="left" rowspan="1" colspan="1">44&#x02013;158</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Gag</bold>(SFU/million)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mean</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">85</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">median</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">83</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25&#x02013;75&#x00025;ile</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">68&#x02013;95</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">range</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">48&#x02013;133</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nef Tat</bold>(SFU/million)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mean</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">median</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">96</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25&#x02013;75&#x00025;ile</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">82&#x02013;115</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">range</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">75&#x02013;128</td></tr></tbody></table></alternatives></table-wrap><p>As shown in <xref ref-type="fig" rid="pone-0019252-g003">Figure 3A</xref>,
delivery of the same dose of ADVAX via EP (HD-EP) resulted in a 70-fold increase
in the mean IFN&#x003b3; ELISpot response to Env over the HD-IM response at Week 10,
the time of peak cellular immune response after the second vaccination.
Responses to the Pol, Gag, and Nef-Tat antigens in the HD-EP group increased by
22, 13, and 19 fold over the mean HD-IM IFN&#x003b3; ELISpot, respectively. There
was a clear dose response in the fold increase to each antigen, as the MD-EP
IFN&#x003b3; ELISPOT responses to Env, Pol, Gag, and Nef-Tat increased by 40, 7, 3,
and 5-fold over HD-IM responses, respectively. There was no correlation between
age of volunteer and magnitude of IFN&#x003b3; ELISpot response within any of the
groups.</p><fig id="pone-0019252-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.g003</object-id><label>Figure 3</label><caption><title>Cellular Immune Response.</title><p>Panel A depicts the fold increase over the HD-IM response in the mean of
all IFN&#x003b3; ELISpot responses to each antigen at Week 10, coinciding
with the peak cellular immune response. Panel B depicts the sum of all
mean ELISpot counts for each peptide pool at each study time point for
all ADVAX dose groups, color coded by antigen. SFU
&#x0200a;=&#x0200a; spot forming units.</p></caption><graphic xlink:href="pone.0019252.g003"/></fig><p>
<xref ref-type="fig" rid="pone-0019252-g003">Figure 3B</xref> depicts the sum of
all mean IFN&#x003b3; ELISpot background-subtracted counts for each antigen over
time by dose group. The magnitude of response increased in the electroporation
groups in a dose-dependent manner. The strongest IFN&#x003b3; ELISPOT responses were
to Env, and the weakest were to Gag. Responses persisted in 1/8 volunteers in
the MD-EP and 2/8 volunteers in the HD-EP group until the end of the trial (Week
56).</p><p>
<xref ref-type="fig" rid="pone-0019252-g004">Figure 4</xref> depicts all
individual background-subtracted IFN&#x003b3; ELISpot counts for each peptide pool
at Week 10. One volunteer in the HD-EP group missed the Week 10 visit, but
completed all subsequent study visits. For each antigen, the magnitude of the
background-subtracted count in the MD-EP and HD-EP groups tended to be higher
than in the HD-IM group, although only statistically significant (p&#x0003c;.017)
p-values are depicted on the graph. The difference in background-subtracted SFU
between the LD-EP and HD-IM groups and between the Placebo-EP and HD-IM groups
was not statistically significant.</p><fig id="pone-0019252-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019252.g004</object-id><label>Figure 4</label><caption><title>Individual IFN&#x003b3; ELISpot Responses.</title><p>All individual background-subtracted IFN&#x003b3; ELISpot counts to each
antigen at study Week 10, the peak response after the second
administration. Horizontal lines indicate median values for each group.
P-values indicate pair-wise comparisons of the three EP responses with
HD-IM responses using the non-parametric Wilcoxon 2-sample test (t
approximation). Significance is set at p&#x0003c;0.017, since there are 3
tests per antigen. Significant p values are depicted. SFU
&#x0200a;=&#x0200a; spot forming units.</p></caption><graphic xlink:href="pone.0019252.g004"/></fig><p>Phenotypic analyses of the HD-EP T-cell responses at the time of peak IFN&#x003b3;
ELISpot response after the third vaccination are summarized in <xref ref-type="supplementary-material" rid="pone.0019252.s001">Figure S1</xref>.
Seven of 8 volunteers mounted responses detectable by ICS, of which 4 formed
CD3&#x0002b; CD4&#x0002b; responses alone, 2 formed both CD3&#x0002b; CD4&#x0002b; and
CD3&#x0002b; CD8&#x0002b; responses, and one formed only a CD3&#x0002b; CD8&#x0002b; T cell
response. The majority of responses were to Env, although 5/7 (71&#x00025;) were
to more than one antigen. <xref ref-type="supplementary-material" rid="pone.0019252.s001">Figure S1</xref> B indicates the distribution of
IFN&#x003b3;, IL-2, MIP1&#x003b2;, and TNF&#x003b1; co-secretion in the CD3&#x0002b; CD4&#x0002b;
and CD3&#x0002b; CD8&#x0002b; T cell compartments. The majority of responding cells in
both the CD4&#x0002b; and CD8&#x0002b; compartments expressed a CD45RO&#x0002b;,
CD27&#x0002b; phenotype.</p></sec><sec id="s3e"><title>Humoral Immunogenicity</title><p>Only one volunteer in the HD-IM group developed weak binding antibodies to clade
C gp120 at 1&#x02236;50 serum dilution one week following vaccination that was
sustained until week 8, after which time he was lost to follow up. All other
responses in all volunteers at all time points were negative. One volunteer in
the HD-EP group tested positive on HIV-1 ELISA at Week 56 with a simultaneous
indeterminate western blot expressing a single gp160 band. A follow up test
eight weeks later was negative for HIV-1 ELISA, western blot, and RNA-PCR
(undetectable at &#x0003c;50 copies/mL).</p></sec></sec><sec id="s4"><title>Discussion</title><p>This is the first demonstration that <italic>in vivo</italic> EP delivery of a DNA
vaccine is safe, tolerable and acceptable to healthy volunteers. The level of
tolerability was independent of age, gender, body weight, skin fold thickness,
handedness, or sequence of vaccination, implying that such a technique could be
evaluated on a wider population scale.</p><p>
<xref ref-type="table" rid="pone-0019252-t003">Table 3</xref> and <xref ref-type="fig" rid="pone-0019252-g003">Figure 3</xref> demonstrate that EP
significantly improves the cellular immune response rate, magnitude, duration, and
breadth of response to multiple antigens, consistent with previous results
demonstrating the improved effect of EP in animal models and in humans with cancer
<xref rid="pone.0019252-Sersa1" ref-type="bibr">[33]</xref>&#x02013;<xref rid="pone.0019252-Low1" ref-type="bibr">[35]</xref>. Vaccination with the same 4 mg dose with and without EP
increased the cellular immune response rate from 0 to 88&#x00025;. As indicated in
<xref ref-type="fig" rid="pone-0019252-g003">Figure 3A</xref>, the predominant
responses were directed against Env, which may be due to differences in expression
of the various genes in ADVAX, or due to a natural immunodominance. HIV-1 Env has
been shown to induce preferentially higher immune responses in humans vaccinated
with a multigenic viral-vectored vaccine <xref rid="pone.0019252-McCormack1" ref-type="bibr">[38]</xref>.</p><p>The average magnitude of the anti-Env response in the HD-EP recipients was 70-fold
higher than the mean response to the same antigen at the same dose delivered by
standard IM injection (HD-IM). There was also a 22, 13, and 19 fold increase in the
mean IFN&#x003b3; ELIspot response to Pol, Gag, and Nef-Tat, respectively, a significant
improvements over the 2&#x02013;6 fold increases in cellular immunity to DNA vaccines
afforded by cytokine adjuvants such as IL-12 and/or IL-15 in non-human primate
studies <xref rid="pone.0019252-Chong1" ref-type="bibr">[39]</xref>. EP
also provided a dose-sparing effect, as the 1 mg dose also improved the immune
response rate over the 4 mg IM vaccination. In addition, as shown in <xref ref-type="fig" rid="pone-0019252-g003">Figure 3B</xref>, these responses were
durable, persisting through the end of the study, and broad, directed to multiple
genes expressed by the vaccine. It has been well-documented that immune reponses to
vaccines decrease with age <xref rid="pone.0019252-Weiskopf1" ref-type="bibr">[40]</xref>. It is therefore encouraging that the magnitude of
ELISPOT responses did not wane with age, and were well-distributed among the
volunteers, aged 18&#x02013;59.</p><p>Phenotyping of these responses by ICS demonstrated that this T cell response tended
to be a CD4&#x0002b; T cell response, although a balanced CD4/8 response could also be
detected in 29&#x00025; of samples tested. The ability to elicit a strong CD4&#x0002b; T
cell response is one characteristic of DNA vaccines, in comparison to some viral
vectors, which tend to elicit a predominantly CD8&#x0002b; effector response <xref rid="pone.0019252-Asmuth1" ref-type="bibr">[41]</xref>. EP delivery
also improved the quality of the T-cell response, by inducing parallel secretion of
IFN&#x003b3;, IL-2, TNF&#x003b1;, and MIP1&#x003b2; in response to multiple antigens (<xref ref-type="supplementary-material" rid="pone.0019252.s001">Figure S1</xref>).
These qualities have been associated with long-term improved control of HIV-1
infection and vaccine-induced protection from simian immunodeficiency virus (SIV) in
monkeys <xref rid="pone.0019252-Betts1" ref-type="bibr">[42]</xref>, <xref rid="pone.0019252-Letvin1" ref-type="bibr">[43]</xref>, although
correlates of protection required for an effective HIV-1 vaccine remain unknown
<xref rid="pone.0019252-Vasan2" ref-type="bibr">[44]</xref>.</p><p>There is a wealth of data in animals demonstrating the ability of EP to improve the
magnitude, duration, and quality of the humoral response to DNA vaccines <xref rid="pone.0019252-Manam1" ref-type="bibr">[18]</xref>&#x02013;<xref rid="pone.0019252-Livingston1" ref-type="bibr">[30]</xref>, including
preliminary reports in humans <xref rid="pone.0019252-Low1" ref-type="bibr">[35]</xref>. The low humoral responses in this study were likely due
to characteristics of ADVAX, rather than ineffectiveness of the EP procedure, given
the fact that ADVAX was initially designed to prime cellular immune responses to a
matched modified Vaccinia Ankara (MVA)-based viral vaccine <xref rid="pone.0019252-Huang1" ref-type="bibr">[36]</xref>, rather than elicit humoral
immunogenicity. ADAVX did not elicit a humoral response in humans after 3 IM
vaccinations in a previous Phase 1 clinical trial <xref rid="pone.0019252-Vasan1" ref-type="bibr">[37]</xref>.</p><p>In addition to these immunological advantages, DNA vaccines confer practical
advantages for large scale global preventive vaccine campaigns, including the
ability for repeated vaccination, relatively low cost and ease of manufacture, and
favorable stability profile, even at higher temperatures. This report demonstrates
that stand alone DNA vaccine regimens can elicit robust cellular immunogenicity in a
dose-dependent manner when delivered by <italic>in vivo</italic> EP. In the future,
this immunogenicity could be further enhanced by improving DNA vector design,
delivering DNA at higher concentrations, with repeated administrations, and in
conjunction with adjuvants. EP delivery of DNA vaccines may also improve priming
before boosting with viral-vectored or protein vaccines. In parallel,
electroporation devices are being re-engineered to be smaller and more portable.
Thus, DNA-EP vaccine strategies may prove to be a promising approach to the
prevention and/or treatment of multiple diseases, not limited to HIV-1.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0019252.s001"><label>Figure S1</label><caption><p>
<bold>Phenotypic Analysis of Antigen-Specific T Cell Responses.</bold>
ELISpot responders from the high dose EP group were characterized by
intracellular cytokine staining (ICS) as described in <xref ref-type="sec" rid="s2">Methods</xref>. Panel A represents the distribution of
CD3&#x0002b; CD4&#x0002b; and CD3&#x0002b; CD8&#x0002b; T cell responses. Panel B
depicts the polyfunctionality of the antigen-specific response in each T
cell compartment to all antigens, as assessed by co-secretion of IFN&#x003b3;,
IL-2, TNF&#x003b1;, and/or MIP1&#x003b2;.</p><p>(TIF)</p></caption><media xlink:href="pone.0019252.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0019252.s002"><label>Table S1</label><caption><p>
<bold>Summary of Adverse Events by MedDRA System organ Class (SOC) and Dose
Group.</bold> Number of volunteers experiencing at least one adverse
event in each SOC.</p><p>(DOC)</p></caption><media xlink:href="pone.0019252.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0019252.s003"><label>Protocol S1</label><caption><p>
<bold>Trial protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0019252.s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0019252.s004"><label>Checklist S1</label><caption><p>
<bold>CONSORT checklist.</bold>
</p><p>(DOCX)</p></caption><media xlink:href="pone.0019252.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors wish to thank the Clinical and Translational Science Award at the
Rockefeller University and its associated staff for assistance in conducting this
clinical trial; the New York City Department of Public Health Laboratories for HIV
testing; Edward Charles, M.D., and Jorge Ortiz for monitoring HIV-1 status; members
of our Data Safety Monitoring Board; and most importantly, our dedicated clinical
trial volunteers.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>D. Hannaman and R. Bernard are employees of Ichor Medical Systems, Inc,
manufacturer of the TriGrid<sup>TM</sup> device. These authors had a direct role
in study design, data collection and analysis, decision to publish, and
preparation of the manuscript. Len Dally and Carol Smith are employed by The
EMMES Corporation. All other authors have no competing financial interests. The
competeing interests of Ichor Medical Systems and the EMMES Corporation do not
alter the authors' adherance to all PLoS ONE policies on sharing data and
materials.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Funding support for this trial was provided by the Bill and Melinda Gates
Foundation Collaboration for AIDS Vaccine Discovery, Grant # 38648. Support from
the International AIDS Vaccine Initiative (IAVI) was provided in part by USAID
Cooperative Agreement Number GPO-A-00-06-00006-00. The contents of this
manuscript are the responsibility of the authors and do not necessarily reflect
the views of USAID or the US government. Ichor Medical Systems, Inc. provided
funding for the TriGrid<sup>TM</sup> device and for personnel. As D. Hannaman
and R. Bernard are employees of Ichor Medical Systems, Inc, this funder had a
direct role in study design, data collection and analysis, decision to publish,
and preparation of the manuscript. The EMMES Corporation provided funding for
personnel. Len Dally and Carol Smith are employees of the EMMES Corporation, and
had a direct role in database design, data analysis, and manuscript preparation.
Other funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0019252-Ulmer1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ulmer</surname><given-names>JB</given-names></name><name><surname>Donnelly</surname><given-names>JJ</given-names></name><name><surname>Parker</surname><given-names>SE</given-names></name><name><surname>Rhodes</surname><given-names>GH</given-names></name><name><surname>Felgner</surname><given-names>PL</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>Heterologous protection against influenza by injection of DNA
encoding a viral protein.</article-title>
<source>Science</source>
<volume>259</volume>
<fpage>1745</fpage>
<lpage>1749</lpage>
<pub-id pub-id-type="pmid">8456302</pub-id></element-citation></ref><ref id="pone.0019252-Donnelly1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>JJ</given-names></name><name><surname>Wahren</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>MA</given-names></name></person-group>
<year>2005</year>
<article-title>DNA vaccines: progress and challenges.</article-title>
<source>J Immunol</source>
<volume>175</volume>
<issue>2</issue>
<fpage>633</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="pmid">16002657</pub-id></element-citation></ref><ref id="pone.0019252-Rice1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rice</surname><given-names>J</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Stevenson</surname><given-names>FK</given-names></name></person-group>
<year>2008</year>
<article-title>DNA vaccines: precision tools for activating effective immunity
against cancer.</article-title>
<source>Nat Rev Cancer</source>
<volume>8</volume>
<fpage>108</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="pmid">18219306</pub-id></element-citation></ref><ref id="pone.0019252-Wang1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Doolan</surname><given-names>DL</given-names></name><name><surname>Le</surname><given-names>TP</given-names></name><name><surname>Hedstrom</surname><given-names>RC</given-names></name><name><surname>Coonan</surname><given-names>KM</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Induction of antigen-specific cytotoxic T lymphocytes in humans
by a malaria DNA vaccine.</article-title>
<source>Science</source>
<volume>282</volume>
<fpage>476</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="pmid">9774275</pub-id></element-citation></ref><ref id="pone.0019252-Rottinghaus1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rottinghaus</surname><given-names>ST</given-names></name><name><surname>Poland</surname><given-names>GA</given-names></name><name><surname>Jacobson</surname><given-names>RM</given-names></name><name><surname>Barr</surname><given-names>LJ</given-names></name><name><surname>Roy</surname><given-names>MJ</given-names></name></person-group>
<year>2003</year>
<article-title>epatitis DNA vaccine induces protective antibody responses in
human nonresponders to conventional vaccination.</article-title>
<source>Vaccine</source>
<volume>21</volume>
<fpage>4604</fpage>
<lpage>4608</lpage>
<pub-id pub-id-type="pmid">14575774</pub-id></element-citation></ref><ref id="pone.0019252-Catanzaro1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Catanzaro</surname><given-names>AT</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Enama</surname><given-names>ME</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA
candidate vaccine.</article-title>
<source>Vaccine</source>
<volume>25</volume>
<fpage>4085</fpage>
<lpage>4092</lpage>
<pub-id pub-id-type="pmid">17391815</pub-id></element-citation></ref><ref id="pone.0019252-Graham1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Enama</surname><given-names>ME</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Phase I Safety and Immunogenicity Evaluation of a Multiclade
HIV-1 Candidate DNA Vaccine.</article-title>
<source>J Infect Dis</source>
<volume>194</volume>
<fpage>1650</fpage>
<lpage>1660</lpage>
<pub-id pub-id-type="pmid">17109336</pub-id></element-citation></ref><ref id="pone.0019252-Kutzler1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kutzler</surname><given-names>MA</given-names></name><name><surname>Weiner</surname><given-names>DB</given-names></name></person-group>
<year>2008</year>
<article-title>DNA vaccines: ready for prime time?</article-title>
<source>Nat Rev Genet</source>
<volume>9</volume>
<fpage>776</fpage>
<lpage>788</lpage>
<pub-id pub-id-type="pmid">18781156</pub-id></element-citation></ref><ref id="pone.0019252-McConkey1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McConkey</surname><given-names>SJ</given-names></name><name><surname>Reece</surname><given-names>WH</given-names></name><name><surname>Moorthy</surname><given-names>VS</given-names></name><name><surname>Webster</surname><given-names>D</given-names></name><name><surname>Dunachie</surname><given-names>S</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by
recombinant modified vaccinia virus Ankara in humans.</article-title>
<source>Nat Med</source>
<volume>9</volume>
<fpage>729</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="pmid">12766765</pub-id></element-citation></ref><ref id="pone.0019252-Harari1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harari</surname><given-names>A</given-names></name><name><surname>Bart</surname><given-names>PA</given-names></name><name><surname>St&#x000f6;hr</surname><given-names>W</given-names></name><name><surname>Tapia</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces
reliable, polyfunctional, and long-lasting T cell responses.</article-title>
<source>J Exp Med</source>
<volume>205</volume>
<fpage>63</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">18195071</pub-id></element-citation></ref><ref id="pone.0019252-Jaoko1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaoko</surname><given-names>W</given-names></name><name><surname>Nakwagala</surname><given-names>FN</given-names></name><name><surname>Anzala</surname><given-names>O</given-names></name><name><surname>Manyonyi</surname><given-names>GO</given-names></name><name><surname>Birungi</surname><given-names>J</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Safety and immunogenicity of recombinant low-dosage HIV-1 A
vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus
Ankara (MVA) in humans in East Africa.</article-title>
<source>Vaccine</source>
<volume>26</volume>
<fpage>2788</fpage>
<lpage>2795</lpage>
<pub-id pub-id-type="pmid">18440674</pub-id></element-citation></ref><ref id="pone.0019252-Goonetilleke1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goonetilleke</surname><given-names>N</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Dally</surname><given-names>L</given-names></name><name><surname>Winstone</surname><given-names>N</given-names></name><name><surname>Cebere</surname><given-names>I</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Induction of multifunctional human immunodeficiency virus type 1
(HIV-1)-specific T cells capable of proliferation in healthy subjects by
using a prime-boost regimen of DNA- and modified vaccinia virus
Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8&#x0002b; T-cell
epitopes.</article-title>
<source>Virol</source>
<volume>80</volume>
<fpage>4717</fpage>
<lpage>4728</lpage>
</element-citation></ref><ref id="pone.0019252-Wang2"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kennedy</surname><given-names>JS</given-names></name><name><surname>West</surname><given-names>K</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Coley</surname><given-names>S</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Cross-subtype antibody and cellular immune responses induced by a
polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human
volunteers.</article-title>
<source>Vaccine</source>
<volume>26</volume>
<fpage>3947</fpage>
<lpage>3957</lpage>
<pub-id pub-id-type="pmid">18724414</pub-id></element-citation></ref><ref id="pone.0019252-Nwanegbo1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nwanegbo</surname><given-names>E</given-names></name><name><surname>Vardas</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Prevalence of neutralizing antibodies to adenoviral serotypes 5
and 35 in the adult populations of The Gambia, South Africa, and the United
States.</article-title>
<source>Clin Diagn Lab Immunol</source>
<volume>11</volume>
<fpage>351</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="pmid">15013987</pub-id></element-citation></ref><ref id="pone.0019252-Mast1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mast</surname><given-names>TC</given-names></name><name><surname>Kierstead</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>SB</given-names></name><name><surname>Nikas</surname><given-names>AA</given-names></name><name><surname>Kallas</surname><given-names>EG</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>International epidemiology of human pre-existing adenovirus (Ad)
type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of
high Ad5 titers and implications for potential HIV vaccine
trials.</article-title>
<source>Vaccine</source>
<volume>28</volume>
<fpage>950</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="pmid">19925902</pub-id></element-citation></ref><ref id="pone.0019252-Santra1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santra</surname><given-names>S</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name><name><surname>Lord</surname><given-names>CI</given-names></name></person-group>
<year>2005</year>
<article-title>Replication-defective adenovirus serotype 5 vectors elicit
durable cellular and humoral immune responses in nonhuman
primates.</article-title>
<source>J Virol</source>
<volume>79</volume>
<fpage>6516</fpage>
<lpage>6522</lpage>
<pub-id pub-id-type="pmid">15858035</pub-id></element-citation></ref><ref id="pone.0019252-Schalk1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schalk</surname><given-names>JA</given-names></name><name><surname>Mooi</surname><given-names>FR</given-names></name><name><surname>Berbers</surname><given-names>GA</given-names></name><name><surname>van Aerts</surname><given-names>LA</given-names></name><name><surname>Ovelg&#x000f6;nne</surname><given-names>H</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Preclinical and clinical safety studies on DNA
vaccines.</article-title>
<source>Hum Vaccin</source>
<volume>2</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">17012886</pub-id></element-citation></ref><ref id="pone.0019252-Manam1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manam</surname><given-names>S</given-names></name><name><surname>Ledwith</surname><given-names>BJ</given-names></name><name><surname>Barnum</surname><given-names>AB</given-names></name><name><surname>Troilo</surname><given-names>PJ</given-names></name><name><surname>Pauley</surname><given-names>CJ</given-names></name></person-group>
<year>2000</year>
<article-title>Plasmid DNA vaccines: tissue distribution and effects of DNA
sequence, adjuvants and delivery method on integration into host
DNA.</article-title>
<source>Intervirology</source>
<volume>43</volume>
<fpage>273</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="pmid">11251382</pub-id></element-citation></ref><ref id="pone.0019252-Mathiesen1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mathiesen</surname><given-names>I</given-names></name></person-group>
<year>1999</year>
<article-title>Electropermeabilization of skeletal muscle enhances gene transfer
in vivo.</article-title>
<source>Gene Ther</source>
<volume>6</volume>
<fpage>508</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">10476210</pub-id></element-citation></ref><ref id="pone.0019252-Widera1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Widera</surname><given-names>G</given-names></name><name><surname>Austin</surname><given-names>M</given-names></name><name><surname>Rabussay</surname><given-names>D</given-names></name><name><surname>Goldbeck</surname><given-names>C</given-names></name><name><surname>Barnett</surname><given-names>SW</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Increased DNA vaccine delivery and immunogenicity by
electroporation in vivo.</article-title>
<source>J Immunol</source>
<volume>164</volume>
<fpage>4635</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">10779767</pub-id></element-citation></ref><ref id="pone.0019252-Babiuk1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Babiuk</surname><given-names>S</given-names></name><name><surname>Baca-Estrada</surname><given-names>ME</given-names></name><name><surname>Foldvari</surname><given-names>M</given-names></name><name><surname>Middleton</surname><given-names>DM</given-names></name><name><surname>Rabussay</surname><given-names>D</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Increased gene expression and inflammatory cell infiltration
caused by electroporation are both important for improving the efficacy of
DNA vaccines.</article-title>
<source>J Biotechnol</source>
<volume>110</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">15099900</pub-id></element-citation></ref><ref id="pone.0019252-Liu1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Kjeken</surname><given-names>R</given-names></name><name><surname>Mathiesen</surname><given-names>I</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group>
<year>2008</year>
<article-title>Recruitment of antigen-presenting cells to the site of
inoculation and augmentation of human immunodeficiency virus type 1 DNA
vaccine immunogenicity by in vivo electroporation.</article-title>
<source>J Virol</source>
<volume>82</volume>
<fpage>5643</fpage>
<lpage>5649</lpage>
<pub-id pub-id-type="pmid">18353952</pub-id></element-citation></ref><ref id="pone.0019252-Babiuk2"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Babiuk</surname><given-names>S</given-names></name><name><surname>Baca-Estrada</surname><given-names>ME</given-names></name><name><surname>Foldvari</surname><given-names>M</given-names></name><name><surname>Storms</surname><given-names>M</given-names></name><name><surname>Rabussay D et</surname><given-names>al</given-names></name></person-group>
<year>2002</year>
<article-title>Electroporation improves the efficacy of DNA vaccines in large
animals.</article-title>
<source>Vaccine</source>
<volume>20</volume>
<fpage>3399</fpage>
<lpage>3408</lpage>
<pub-id pub-id-type="pmid">12213410</pub-id></element-citation></ref><ref id="pone.0019252-Luxembourg1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luxembourg</surname><given-names>A</given-names></name><name><surname>Hannaman</surname><given-names>D</given-names></name><name><surname>Ellefsen</surname><given-names>B</given-names></name><name><surname>Nakamura</surname><given-names>G</given-names></name><name><surname>Bernard</surname><given-names>R</given-names></name></person-group>
<year>2006</year>
<article-title>Enhancement of immune responses to an HBV DNA vaccine by
electroporation.</article-title>
<source>Vaccine</source>
<volume>24</volume>
<fpage>4490</fpage>
<lpage>4493</lpage>
<pub-id pub-id-type="pmid">16140436</pub-id></element-citation></ref><ref id="pone.0019252-Li1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>DNA electroporation prime and protein boost strategy enhances
humoral immunity of tuberculosis DNA vaccines in mice and non-human
primates.</article-title>
<source>Vaccine</source>
<volume>24</volume>
<fpage>4565</fpage>
<lpage>4568</lpage>
<pub-id pub-id-type="pmid">16154246</pub-id></element-citation></ref><ref id="pone.0019252-Hooper1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hooper</surname><given-names>JW</given-names></name><name><surname>Golden</surname><given-names>JW</given-names></name><name><surname>Ferro</surname><given-names>AM</given-names></name><name><surname>King</surname><given-names>AD</given-names></name></person-group>
<year>2007</year>
<article-title>Smallpox DNA vaccine delivered by novel skin electroporation
device protects mice against intranasal poxvirus challenge.</article-title>
<source>Vaccine</source>
<volume>25</volume>
<fpage>1814</fpage>
<lpage>1823</lpage>
<pub-id pub-id-type="pmid">17240007</pub-id></element-citation></ref><ref id="pone.0019252-Luckay1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luckay</surname><given-names>A</given-names></name><name><surname>Sidhu</surname><given-names>MK</given-names></name><name><surname>Kjeken</surname><given-names>R</given-names></name><name><surname>Megati</surname><given-names>S</given-names></name><name><surname>Chong</surname><given-names>SY</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Effect of plasmid DNA vaccine design and in vivo electroporation
on the resulting vaccine-specific immune responses in rhesus
macaques.</article-title>
<source>J Virol</source>
<volume>81</volume>
<fpage>5257</fpage>
<lpage>5269</lpage>
<pub-id pub-id-type="pmid">17329330</pub-id></element-citation></ref><ref id="pone.0019252-Dobao1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doba&#x000f1;o</surname><given-names>C</given-names></name><name><surname>Widera</surname><given-names>G</given-names></name><name><surname>Rabussay</surname><given-names>D</given-names></name><name><surname>Doolan</surname><given-names>DL</given-names></name></person-group>
<year>2007</year>
<article-title>Enhancement of antibody and cellular immune responses to malaria
DNA vaccines by in vivo electroporation.</article-title>
<source>Vaccine</source>
<volume>25</volume>
<fpage>6635</fpage>
<lpage>6645</lpage>
<pub-id pub-id-type="pmid">17669562</pub-id></element-citation></ref><ref id="pone.0019252-Hirao1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirao</surname><given-names>LA</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>AS</given-names></name><name><surname>Hokey</surname><given-names>DA</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Combined effects of IL-12 and electroporation enhances the
potency of DNA vaccination in macaques.</article-title>
<source>Vaccine</source>
<volume>26</volume>
<fpage>3112</fpage>
<lpage>3120</lpage>
<pub-id pub-id-type="pmid">18430495</pub-id></element-citation></ref><ref id="pone.0019252-Livingston1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Livingston</surname><given-names>BD</given-names></name><name><surname>Little</surname><given-names>SF</given-names></name><name><surname>Luxembourg</surname><given-names>A</given-names></name><name><surname>Ellefsen</surname><given-names>B</given-names></name><name><surname>Hannaman</surname><given-names>D</given-names></name></person-group>
<year>2010</year>
<article-title>Comparative performance of a licensed anthrax vaccine versus
electroporation based delivery of a PA encoding DNA vaccine in rhesus
macaques.</article-title>
<source>Vaccine</source>
<volume>28</volume>
<issue>4</issue>
<fpage>1056</fpage>
<lpage>1061</lpage>
<pub-id pub-id-type="pmid">19896452</pub-id></element-citation></ref><ref id="pone.0019252-Rosati1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosati</surname><given-names>M</given-names></name><name><surname>Valentin</surname><given-names>A</given-names></name><name><surname>Jalah</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>von Gegerfelt</surname><given-names>A</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Increased immune responses in rhesus macaques by DNA vaccination
combined with electroporation.</article-title>
<source>Vaccine</source>
<volume>26</volume>
<issue>40</issue>
<fpage>5223</fpage>
<lpage>5229</lpage>
<pub-id pub-id-type="pmid">18468743</pub-id></element-citation></ref><ref id="pone.0019252-Chen1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>MW</given-names></name><name><surname>Cheng</surname><given-names>TJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jan</surname><given-names>JT</given-names></name><name><surname>Ma</surname><given-names>SH</given-names></name><name><surname>Yu</surname><given-names>AL</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>A consensus-hemagglutinin-based DNA vaccine that protects mice
against divergent H5N1 influenza viruses.</article-title>
<source>Proc Natl Acad Sci U SA</source>
<volume>105</volume>
<fpage>13538</fpage>
<lpage>13543</lpage>
</element-citation></ref><ref id="pone.0019252-Sersa1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sersa</surname><given-names>G</given-names></name><name><surname>Miklavcic</surname><given-names>D</given-names></name><name><surname>Cemazar</surname><given-names>M</given-names></name><name><surname>Rudolf</surname><given-names>Z</given-names></name><name><surname>Pucihar</surname><given-names>G</given-names></name><name><surname>Snoj</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>Electrochemotherapy in treatment of tumours.</article-title>
<source>Eur J Surg Oncol</source>
<volume>34</volume>
<fpage>232</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="pmid">17614247</pub-id></element-citation></ref><ref id="pone.0019252-Stevenson1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>FK</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Johnson</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Buchan</surname><given-names>SL</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>DNA vaccines to attack cancer.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>101</volume>
<issue>Suppl 2</issue>
<fpage>14646</fpage>
<lpage>14652</lpage>
<pub-id pub-id-type="pmid">15292504</pub-id></element-citation></ref><ref id="pone.0019252-Low1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Low</surname><given-names>L</given-names></name><name><surname>Mander</surname><given-names>A</given-names></name><name><surname>McCann</surname><given-names>K</given-names></name><name><surname>Dearnaley</surname><given-names>D</given-names></name><name><surname>Tjelle</surname><given-names>T</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>DNA vaccination with electroporation induces increased antibody
responses in patients with prostate cancer.</article-title>
<source>Hum Gene Ther</source>
<volume>20</volume>
<fpage>1269</fpage>
<lpage>1278</lpage>
<pub-id pub-id-type="pmid">19619001</pub-id></element-citation></ref><ref id="pone.0019252-Huang1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Gurner</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Design, construction, and characterization of a dual-promoter
multigenic DNA vaccine directed against an HIV-1 subtype C/B'
recombinant.</article-title>
<source>J Acquir Immune Defic Syndr</source>
<volume>47</volume>
<fpage>403</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="pmid">18209683</pub-id></element-citation></ref><ref id="pone.0019252-Vasan1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasan</surname><given-names>S</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Lombardo</surname><given-names>A</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a
Multigenic, DNA-based Clade C/B' HIV-1 Candidate
Vaccine.</article-title>
<source>PLOS One</source>
<volume>5</volume>
<issue>1</issue>
<fpage>e8617, p1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">20111582</pub-id></element-citation></ref><ref id="pone.0019252-McCormack1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCormack</surname><given-names>S</given-names></name><name><surname>St&#x000f6;hr</surname><given-names>W</given-names></name><name><surname>Barber</surname><given-names>T</given-names></name><name><surname>Bart</surname><given-names>PA</given-names></name><name><surname>Harari</surname><given-names>A</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>EV02: a Phase I trial to compare the safety and immunogenicity of
HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.</article-title>
<source>Vaccine</source>
<volume>26</volume>
<fpage>3162</fpage>
<lpage>3174</lpage>
<pub-id pub-id-type="pmid">18502003</pub-id></element-citation></ref><ref id="pone.0019252-Chong1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chong</surname><given-names>SY</given-names></name><name><surname>Egan</surname><given-names>MA</given-names></name><name><surname>Kutzler</surname><given-names>MA</given-names></name><name><surname>Megati</surname><given-names>S</given-names></name><name><surname>Masood</surname><given-names>A</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Comparative ability of plasmid IL-12 and IL-15 to enhance
cellular and humoral immune responses elicited by a SIVgag plasmid DNA
vaccine and alter disease progression following SHIV89.6P challenge in
rhesus macaques.</article-title>
<source>Vaccine</source>
<volume>25</volume>
<fpage>4967</fpage>
<lpage>4982</lpage>
<pub-id pub-id-type="pmid">17335943</pub-id></element-citation></ref><ref id="pone.0019252-Weiskopf1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Weinberger</surname><given-names>B</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B</given-names></name></person-group>
<year>2009</year>
<article-title>The aging of the immune system.</article-title>
<source>Transpl Int</source>
<volume>22</volume>
<fpage>1041</fpage>
<lpage>1050</lpage>
<pub-id pub-id-type="pmid">19624493</pub-id></element-citation></ref><ref id="pone.0019252-Asmuth1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asmuth</surname><given-names>DM</given-names></name><name><surname>Brown</surname><given-names>EL</given-names></name><name><surname>DiNubile</surname><given-names>MJ</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>del Rio</surname><given-names>C</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Comparative cell-mediated immunogenicity of DNA/DNA,
DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine
prime-boost regimens.</article-title>
<source>J Infect Dis</source>
<volume>201</volume>
<fpage>132</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">19929694</pub-id></element-citation></ref><ref id="pone.0019252-Betts1"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name><name><surname>West</surname><given-names>SM</given-names></name><name><surname>De Rosa</surname><given-names>SC</given-names></name><name><surname>Migueles</surname><given-names>SA</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>HIV nonprogressors preferentially maintain highly functional
HIV-specific CD8&#x0002b; T-cells.</article-title>
<source>Blood</source>
<volume>107</volume>
<fpage>4781</fpage>
<lpage>4789</lpage>
<pub-id pub-id-type="pmid">16467198</pub-id></element-citation></ref><ref id="pone.0019252-Letvin1"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Letvin</surname><given-names>NL</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Gorgone</surname><given-names>DA</given-names></name><name><surname>Buzby</surname><given-names>AP</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Preserved CD4&#x0002b; central memory T cells and survival in
vaccinated SIV-challenged monkeys.</article-title>
<source>Science</source>
<volume>312</volume>
<fpage>1530</fpage>
<lpage>1533</lpage>
<pub-id pub-id-type="pmid">16763152</pub-id></element-citation></ref><ref id="pone.0019252-Vasan2"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasan</surname><given-names>S</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Arrode</surname><given-names>G</given-names></name></person-group>
<year>2007</year>
<article-title>T-Cell Immune Responses to HIV-1.</article-title>
<source>Front Biosci</source>
<volume>12</volume>
<fpage>2330</fpage>
<lpage>2343</lpage>
<pub-id pub-id-type="pmid">17127243</pub-id></element-citation></ref></ref-list></back></article>